皮疹
不利影响
胶质瘤
IDH1
恶心
医学
内科学
胃肠病学
药理学
肿瘤科
突变体
化学
癌症研究
生物化学
基因
作者
Atsushi Natsume,Yoshiki Arakawa,Yoshitaka Narita,Kazuhiko Sugiyama,Nobuhiro Hata,Yoshihiro Muragaki,Naoki Shinojima,Toshihiro Kumabe,Ryuta Saito,Kazuya Motomura,Yohei Mineharu,Yasuji Miyakita,Fumiyuki Yamasaki,Yuko Matsushita,Koichi Ichimura,Kazumi Ito,Masaya Tachibana,Yasuyuki Kakurai,Naoko Okamoto,Takashi Asahi
出处
期刊:Neuro-oncology
[Oxford University Press]
日期:2022-06-20
卷期号:25 (2): 326-336
被引量:97
标识
DOI:10.1093/neuonc/noac155
摘要
BACKGROUND: Approximately 70% of lower-grade gliomas harbor isocitrate dehydrogenase 1 (IDH1) mutations, resulting in the accumulation of oncometabolite D-2-hydroxyglutarate (D-2-HG); this leads to epigenetic dysregulation, oncogenesis, and subsequent clonal expansion. DS-1001 is an oral brain-penetrant mutant IDH1 selective inhibitor. This first-in-human study investigated the safety, pharmacokinetics, pharmacodynamics, and efficacy of DS-1001. METHODS: This was a multicenter, open-label, dose-escalation, phase I study of DS-1001 for recurrent/progressive IDH1-mutant (R132) glioma (N = 47) (NCT03030066). DS-1001 was administered orally at 125-1400 mg twice daily. Dose-escalation used a modified continual reassessment method. RESULTS: The maximum tolerated dose was not reached. Eight patients were continuing treatment at the data cutoff. Most adverse events (AEs) were grade 1-2. Twenty patients (42.6%) experienced at least 1 grade 3 AE. No grade 4 or 5 AEs or serious drug-related AEs were reported. Common AEs (>20%) were skin hyperpigmentation, diarrhea, pruritus, alopecia, arthralgia, nausea, headache, rash, and dry skin. The objective response rates were 17.1% for enhancing tumors and 33.3% for non-enhancing tumors. Median progression-free survival was 10.4 months (95% confidence interval [CI], 6.1 to 17.7 months) and not reached (95% CI, 24.1 to not reached) for the enhancing and non-enhancing glioma cohorts, respectively. Seven on-treatment brain tumor samples showed a significantly lower amount of D-2-HG compared with pre-study archived samples. CONCLUSIONS: DS-1001 was well tolerated with a favorable brain distribution. Recurrent/progressive IDH1-mutant glioma patients responded to treatment. A study of DS-1001 in patients with chemotherapy- and radiotherapy-naïve IDH1-mutated WHO grade 2 glioma is ongoing (NCT04458272).
科研通智能强力驱动
Strongly Powered by AbleSci AI